|
|
Volumn 14, Issue 2, 2007, Pages 150-155
|
|
Perspective of trastuzumab treatment.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
FEMALE;
HEART LEFT VENTRICLE FUNCTION;
HUMAN;
METABOLISM;
MULTIMODALITY CANCER THERAPY;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
BREAST NEOPLASMS;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
FEMALE;
HUMANS;
RECEPTOR, ERBB-2;
VENTRICULAR DYSFUNCTION, LEFT;
|
|
EID: 34548380275
PISSN: 13406868
EISSN: None
Source Type: Journal
DOI: 10.2325/jbcs.955 Document Type: Review |
|
Times cited : (8)
|
|
References (22)
|
